BRAF and cancer: This approach is particularly relevant as BRAF-mutated PTCs and ATCs can be selectively targeted by BRAFi—i.e., vemurafenib and dabrafenib (combined with trametinib in ATC)—whose efficacy has been proven both in BRAFV600E-positive metastatic melanoma [79] and in non-melanoma cancers [65, 80].